Navigating Decentralized Clinical Trials With FDA's Guidance
On Sept. 18, the U.S. Food and Drug Administration issued final guidance titled "Conducting Clinical Trials With Decentralized Elements," for sponsors, investigators and other interested parties to support drug, biologic and...To view the full article, register now.
Already a subscriber? Click here to view full article